argenx SE [NASDAQ: ARGX] has shared its strategic priorities for 2022 and also disclosed its recent accomplishments from its broad immunology pipeline. The Company also reported financial guidance for 2022. The company is looking forward to the year 2022. It has also received its first FDA approval and begun commercialization of VYVGART in the United States.
ARGX is now on its way to achieving its goal of becoming a premier multi-product immunology company, and it has full confidence that it has proper people, a distinctive pipeline, and a long-term development engine to back up its vision, said Tim Van Hauwermeiren, argenx’s Chief Executive Officer.
Furthermore, the strategic priorities for 2022 support the ‘argenx 2025’ vision to become a global, integrated immunology organization. Its priorities include authorization by Japan’s Pharmaceuticals and MAA anticipated during the first quarter of 2022. Its Strategic Priorities include authorization by the European Medicines Agency of MAA anticipated in the second half of 2022.
In addition, the company disclosed that its U.S. commercial launch is in progress after December 2021 authorization by the U.S. FDA of VYVGART for the cure of gMG in adult patients who are anti-acetylcholine receptor antibody-positive. Moreover, its additional collaboration agreements are likely to be disclosed in 2022 that would grow global patient reach.
argenx disclosed that it had nearly $2.3 billion in cash, cash equivalents, and current financial assets as of December 31, 2021. Based on current plans to finance expected operating expenses and capital expenditures, argenx anticipates utilizing nearly half of its available cash in 2022. Moreover, Mr. Van Hauwermeiren will draw attention to these updates in a corporate presentation at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 7:30 a.m. ET.